Roberts Glore & Co. Inc. IL Grows Holdings in Becton, Dickinson and Company $BDX

Roberts Glore & Co. Inc. IL lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,783 shares of the medical instruments supplier’s stock after buying an additional 305 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Becton, Dickinson and Company were worth $1,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its holdings in Becton, Dickinson and Company by 42.6% in the first quarter. U.S. Capital Wealth Advisors LLC now owns 1,745 shares of the medical instruments supplier’s stock valued at $400,000 after buying an additional 521 shares during the last quarter. Cerity Partners LLC increased its holdings in Becton, Dickinson and Company by 174.6% in the first quarter. Cerity Partners LLC now owns 195,850 shares of the medical instruments supplier’s stock valued at $44,862,000 after buying an additional 124,522 shares during the last quarter. Xponance Inc. raised its stake in Becton, Dickinson and Company by 2.9% during the first quarter. Xponance Inc. now owns 42,224 shares of the medical instruments supplier’s stock valued at $9,672,000 after buying an additional 1,198 shares in the last quarter. Finally, Grant GrossMendelsohn LLC lifted its holdings in Becton, Dickinson and Company by 5.6% during the 1st quarter. Grant GrossMendelsohn LLC now owns 1,411 shares of the medical instruments supplier’s stock worth $323,000 after buying an additional 75 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,249 shares of company stock worth $231,358 in the last 90 days. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $177.88 on Friday. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The stock has a market capitalization of $50.99 billion, a price-to-earnings ratio of 31.99, a PEG ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock’s fifty day moving average is $186.77 and its two-hundred day moving average is $182.30.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date is Monday, December 8th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 71.36%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BDX shares. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Jefferies Financial Group decreased their price objective on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a report on Friday. Stifel Nicolaus lowered their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.